Progression of excitation-contraction coupling defects in doxorubicin cardiotoxicity

Archive ouverte

Llach, Anna | Mazevet, Marianne | Mateo, Philippe | Villejoubert, Olivier | Ridoux, Audrey | Rucker-Martin, Catherine | Ribeiro, Maxance | Fischmeister, Rodolphe | Crozatier, Bertrand | Benitah, Jean-Pierre | Morel, Eric | Gómez, Ana Maria

Edité par CCSD ; Elsevier -

International audience. Cardiac failure is a common complication in cancer survivors treated with anthracyclines. Here we followed up cardiac function and excitation-contraction (EC) coupling in an in vivo doxorubicin (Dox) treated mice model (iv, total dose of 10 mg/Kg divided once every three days). Cardiac function was evaluated by echocardiography at 2, 6 and 15 weeks after the last injection. While normal at 2 and 6 weeks, ejection fraction was significantly reduced at 15 weeks. In order to evaluate the underlying mechanisms, we measured [Ca2+]i transients by confocal microscopy and action potentials (AP) by patch-clamp technique in cardiomyocytes isolated at these times. Three phases were observed: 1/ depression and slowing of the [Ca2+]i transients at 2 weeks after treatment, withoccurrence of proarrhythmogenic Ca2+ waves, 2/ compensatory state at 6 weeks, and 3/ depression on [Ca2+]i transients and cell contraction at 15 weeks, concomitant with in vivo defects. These [Ca2+]i transient alterations were observed without cellular hypertrophy or AP prolongation and mirrored the sarcoplasmic reticulum (SR) Ca2+ load variations. At the molecular level, this was associated with a decrease in the sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) expression and enhanced RyR2 phosphorylation at the protein kinase A (PKA, pS2808) site (2 and 15 weeks). RyR2 phosphorylation at the Ca2+/calmodulin dependent protein kinase II (CaMKII, pS2814) site was enhanced only at 2 weeks, coinciding with the higher incidence of proarrhythmogenic Ca2+ waves. Our study highlighted, for the first time, the progression of Dox treatment-induced alterations in Ca2+ handling and identified key components of the underlying Dox cardiotoxicity. These findings should be helpful to understand the early-, intermediate-, and late- cardiotoxicity already recorded in clinic in order to prevent or treat at the subclinical level.

Suggestions

Du même auteur

EPAC1 inhibition protects the heart from doxorubicin-induced toxicity

Archive ouverte | Mazevet, Marianne | CCSD

International audience. Anthracyclines, such as doxorubicin (Dox), are widely used chemotherapeutic agents for the treatment of solid tumors and hematologic malignancies. However, they frequently induce cardiotoxici...

Epac in cardiac calcium signaling

Archive ouverte | Ruiz-Hurtado, Gema | CCSD

International audience

Epac in cardiac calcium signaling.

Archive ouverte | Ruiz-Hurtado, Gema | CCSD

International audience. Epac, exchange protein directly activated by cAMP, is emerging as a new regulator of cardiac physiopathology. Although its effects are much less known than the classical cAMP effector, PKA, s...

Chargement des enrichissements...